In over a decade, Samsung Biologics has rapidly evolved into the world’s largest and best-in-class CDMO service partner. We continue to expand our business scope to make the next leap in biopharma, and build greater capabilities to meet new market demand as a top service innovator in the biopharmaceutical industry, while ensuring quality and a stable supply of life-saving drugs.
Since its launch, Samsung Biologics has not only expanded its manufacturing capacity, but also established a solid track record of successful regulatory approvals and award-winning client satisfaction. In an effort to provide the highest level of customer-centric services, Samsung Biologics implemented innovative technologies and processes to provide speed, price competitiveness, quality, and efficiency.
We are facing a time of significant challenges and market dynamics. To respond to the surging demand for biologics, we began operations at Plant 5, the first facility of our second Bio Campus, in April this year. With three additional plants planned, the full campus is on track for completion by 2032. To strengthen client engagement and provide localized support, Samsung Biologics also has established sales offices in New Jersey, Boston, San Francisco and Tokyo, enabling us to operate in closer proximity with clients across the U.S., Japan and Europe.
We embrace responsibility, expertise, and pride in our work, and will continue to improve the accessibility of biomedicines and consequently the quality of life for people around the globe. We will challenge ourselves to improve in all facets of our business through innovation, dedication, and excellence so that we can add meaningful value to all of our clients, partners, and shareholders.
Thank you for your continuous trust and support.